Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

August 2017

Author(s): Meyer T, Fox R, Ma YT, Ross PJ, James MW, Sturgess R, et al

Details: Lancet Gastroenterol Hepatol

NIHR Acknowledged: Yes

People
Photo Name Bio